Fig. 1From: Biologic predictors of clinical improvement in rituximab-treated refractory myositisDistribution of cytokines scores at the start of treatment by autoantibodies. Groupings include the individual autoantibodies listed and those individuals who had no autoantibodies detected (no autoantibodies), those with myositis-associated autoantibodies but not those listed (other autoAb) and those with autoantibodies that are not able to be defined (undefined)Back to article page